In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance ...

智通财经APP讯， 亚虹医药 (688176.SH) 发布公告，近日，公司产品APL-1702用于治疗宫颈高级别鳞状上皮内病变 (High-Grade Squamous Intraepithelial Lesion, HSIL)的前瞻、随机、双盲、安慰剂对照的国际多中心Ⅲ期临床试验结果已获 Cell Press 旗下《Med》线上发表。《Med》系由Cell Press ...

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...

Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options has not been ...

Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC) ...

Australians led the way with research on the B vitamin nicotinamide to prevent basal and squamous cell skin cancers.

Please provide your email address to receive an email when new articles are posted on . A genomic test predicts individual risk for metastasis after a cutaneous squamous cell carcinoma diagnosis. Two ...

The first reported cases of PKMB appeared in the French literature in the 1960s (Lortat-Jacob & Civatte, 1961). They described a lesion of the glans penis characterized by thick, hyperkeratotic ...

WASHINGTON -- President Joe Biden's doctor said Friday that a lesion removed from the president's chest last month was basal cell carcinoma, a common type of skin cancer. Dr. Kevin O'Connor wrote in a ...